research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Search
for
Sort by
Research
150-180 / 1000+ results
research Adenosine stimulates growth of dermal papilla and lengthens the anagen phase by increasing the cysteine level via fibroblast growth factors 2 and 7 in an organ culture of mouse vibrissae hair follicles
Adenosine helps hair grow longer and stronger by boosting certain growth factors and signaling pathways.
research Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway
Microneedling with 5% minoxidil improves hair loss in Chinese men by activating Wnt/ß-catenin pathway.
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
research Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride − 5% Minoxidil in male androgenetic alopecia
The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.
research Faculty Opinions recommendation of Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial.
research Comparative Study of a Topical and Oral Combination Therapy Containing Oleanolic Acid, Apigenin, and Biotinyl Tripeptide-1 in Patients with Androgenetic Alopecia: A Prospective, Open-Label Trial
The combination therapy improved hair growth and thickness in people with androgenetic alopecia.
research Faculty Opinions recommendation of Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial.
DHEA therapy improved pubic hair growth and psychological well-being in young females with adrenal insufficiency.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss in men.
research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial
Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study
RCS-01 therapy is safe and may improve skin structure by affecting gene expression.
research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
Topical 5% minoxidil is safe and effective for treating hair loss in Korean men.
research Comparison of a New 5% Minoxidil Foam and Rogaine® in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.
research The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
research Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
Low-dose dutasteride effectively and safely promotes hair growth in men.
research 1077 Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
A new hair restoration technology was found to effectively increase hair thickness, density, and growth, while reducing hair loss and improving scalp health, with no side effects.
research Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery
Niosomes are a promising, stable, and cost-effective drug delivery system with potential for improved targeting and safety.
research Ectodysplasin research—Where to next?
Future research on ectodysplasin should explore its role in diseases, stem cells, and evolution, and continue developing treatments for genetic disorders like hypohidrotic ectodermal dysplasia.
research A Novel Approach Against Male Pattern Hair Loss With Topical Dimethylglycine Sodium Salt (DMG ‐Na) and Caffeine: Efficacy of a 24‐Week, Double‐Blind, Randomized, Placebo‐Controlled Trial
The shampoo with DMG-Na and caffeine effectively reduces hair loss and improves hair density in men.